



## Pharmacokinetics/Pharmacodynamics Analysis of Veterinary Antimicrobial Agents

Guest Editor:

### Prof. Dr. Lingli Huang

National Reference Laboratory of Veterinary Drug Residues (HZAU) and MAO Key Laboratory for Detection of Veterinary Drug Residues, Wuhan 430070, China

Deadline for manuscript submissions:

**closed (31 December 2022)**

### Message from the Guest Editor

Irrational use of antimicrobial drugs in animals may result in the development and spread of bacterial resistance, which threatens human and animal health. The pharmacokinetic/pharmacodynamic (PK/PD) model can link pharmacokinetics and pharmacodynamics to evaluate and predict dose–concentration–response relationships. The PK/PD model has been applied in veterinary antimicrobial drugs for two decades, playing a vital role in the rational use of antimicrobial drugs. This Special Edition on One Health between human and animals focuses on the PK/PD model in veterinary antimicrobial drugs in primary care and will consist of 10–15 manuscripts, which may include original research, review articles, case series, and opinion papers. We are interested in both qualitative and quantitative research across the following areas:

1. Application of the PK/PD model in the research and development of new drugs (e.g., preclinical PK/PD, translational PK/PD);
2. Optimization of dosage regimen through the PK/PD model (e.g., PK/PD parameters, combination);
3. Establishment of clinical breakpoint and PK/PD cutoff;
4. Prevention and treatment of drug-resistant bacteria (e.g., HFIM,MSW).





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi